Clinical trials
Cancer
Protocol : GS-US-587-6156
Cancer
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Cancer
KEYNOTE-867
Cancer
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Cancer
ProstACT-TARGET
Cancer
A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer
Cancer
KEYNOTE-C93
Cancer
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Cancer
THIO-101
Cancer
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
Cancer
EpimAb - EMB09X101
Cancer
A First-in-human, Phase I Trial of study drug, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients with Advanced or metastatic Solid Tumours
Breast Cancer
TABITHA
Breast cancer
Heart Disease
Vantage IDE (Enrolment opening soon)
Cardiovascular disease
To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.
Heart Disease
AngelMed (Enrolment opening soon)
Cardiovascular Disease
To evaluate a new device in patients with prior acute coronary syndrome.
Heart Disease
Arrowhead (Enrolment opening soon)
Cardiovascular Disease
To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.
Genitourinary Cancer
SAMETA (D5086C00001)
Genitourinary cancer
Cancer
ICP-CL-003030
Cancer
A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumours and FGFR gene alterations
Prostate Cancer
DECREASE
Prostate cancer
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.
Heart Disease
RO-CARDIAC
Heart disease
Can Coronary Artery Calcium Score identified on thoracic planning ct scans be used and actioned to identify patients at high risk of cardiac events: a feasibility study in patients with cancer undergoing radiotherapy (ro-cardiac)
Colorectal Cancer
AMGEN 20190172
Colorectal cancer
A Phase 3 Multicenter, Randomized, Open-label,Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
Cancer
AMGEN 20190135
Basket – Solid Tumours
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation
Heart Disease
Victorion Plaque
Cardiovascular Disease, Heart Disease
Heart Disease
Victorion-2 Prevent
Heart Disease, Cardiovascular Disease
To evaluate the impact of a new medication on participants who have established cardiovascular disease and who have had a major adverse cardiovascular event.
Prostate Cancer
CONTACT-02
Prostate cancer
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro
Breast Cancer
DESTINY-12
Breast cancer
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Lung Cancer
KRYSTAL-12
Lung cancer
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.
Skin Cancer
Oncobeta EPIC-SKIN (OB-RHSCT-101)
Skin cancer
Efficacy of Personalised Irradiation with Rhenium-SCT Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV, multi-centre, international, open label, single arm study
Prostate Cancer
RADIANT
Prostate cancer
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.
Liver Cancer
SYS-CAPLIOX (AV-LIVPIBII-01)
Liver cancer
The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.
Breast Cancer
HER2 REAL (D9673R00005)
Breast cancer
A Multicountry, Multicentre, Noninterventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer.
Colorectal Cancer
SEAMARK – C4221022
Colorectal Cancer
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL
Prostate Cancer
Prostact-Select
Prostate cancer
Safety, tolerability, biodistribution, dosimetry and efficacy study of 177Lu-DOTA-TLX591-CHO with best standard of care in patients with PSMA expressing metastatic castration-resistant prostate cancer.
Heart Disease
IONIS
Cardiovascular disease
To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).
Heart Disease
HighFLO
Heart failure
To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.
Heart Disease
FINEARTS-HF
Heart failure
To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).
Heart Disease
Cardialen AF CL008
Irregular heart beat
Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure
Heart Disease
ZEUS
Cardiovascular disease
To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.
Heart Disease
CATALYST
Atrial fibrillation
Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.
Breast Cancer
AUS-PREDICT
Breast cancer
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.
Heart Disease
Cardialen AF CL007
Atrial fibrillation
Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure
Heart Disease
VFAHF
Heart failure
To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.
Prostate Cancer
DASL-HiCaP
Prostate cancer
The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.
Cancer
DYNAMIC-III
Bowel cancer
The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.
Prostate Cancer
CUPID
Prostate cancer
This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.
Lung Cancer
AdvanTIG – BGB-A317-A1217-302
Non-small cell lung cancer
The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.
Prostate Cancer
NINJA
Prostate cancer
The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.
Prostate Cancer
ARANOTE
Prostate cancer
This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Pancreatic Cancer
MASTERPLAN
Pancreatic cancer
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
Bladder Cancer
Checkmate-078
Bladder cancer
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.
Bladder Cancer
BCG + MMC
Bladder cancer
Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.
Bladder Cancer
KEYPAD
Metastatic kidney cancer
This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Cancer
DREAM3R
Mesothelioma
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Skin Cancer
GENTLER
Skin cancer
The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.
Skin Cancer
BFSCT
Skin cancer
This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.
CUPisco
Rare tumors
Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).
Cancer
KEYNOTE-992
Bladder cancer
Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).
Breast Cancer
AVATAR
Breast cancer
Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).
Breast Cancer
DESTINY-Breast05
Breast cancer
This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Skin Cancer
CPOST
Skin cancer
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.
Breast Cancer
CONCERTO
Breast cancer
A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.
Prostate Cancer
PRIMORDIUM
Prostate cancer
The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.
Lung Cancer
B8011011
Carcinoma, non-small-cell lung
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).
Non-Melanoma Skin Cancer
EVOLVE
Non-melanoma Skin Cancer
Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.
Prostate Cancer
Telix ENHANCING
Prostate cancer
The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.
Cancer
CHALLENGE
Colon cancer
A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial.
Cancer
ADAPT-MRL
Any cancer
A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.
Lung Cancer
MERMAID-1
Carcinoma, non-small cell lung
The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
Lung Cancer
MERMAID-2
Carcinoma, non-small cell lung
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
Prostate Cancer
PROPELLER
Prostate cancer
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
Prostate Cancer
ENZA-p
Prostate cancer
Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
Dupuytren's Disease
DEPART
Connective tissue disorders
GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.
Heart Disease
PORTICO-NG
Aortic valve stenosis
To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.
Heart Disease
SUCCOUR MRI SUB-STUDY
Heart failure
To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.
Heart Disease
HighLife
Heart failure
To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.
NDROR
Skin registry
To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.
Clinical Trial
EXPERT
Breast cancer
A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.